C-Met mutated NSCLC Market Insight
The total incident cases of C-Met mutated NSCLC in the 7MM was 16,658 in 2017. The C-Met accounted for approximately 4% of the total cases of NSCLC. In 2017, with 7,202 cases the United States had the highest number of C-Met mutated NSCLC cases among the 7MM, while Spain with 869 cases had the lowest registered cases.
The market size of C-Met mutated NSCLC in the 7MM was found to be USD 186 Million in 2017, which is expected to increase during the forecast period 2017-2030.
Increasing use of biomarker testing, increase in mutation specific trials activity, increasing incidence of C-Met mutated NSCLC are some of the key drivers for the C-Met NSCLC market.
The key companies in the C-Met mutated NSCLC market includes Novartis, Merck, Janssen Pharmaceutical, Eli Lilly and Company, AbbVie, Symphogen, Takeda, Exelixis, Ipsen and others.
For more detailed information, visit: https://www.delveinsight.com/report-store/cellular-mesenchymal-epithelial-transition-factor-mutated-non-small-cell-lung-cancer-market